Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
La Jolla Pharmaceutical Co is a biotechnology business based in the US. La Jolla Pharmaceutical shares (LJPC) are listed on the NASDAQ and all prices are listed in US Dollars. La Jolla Pharmaceutical employs 61 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.12 |
|---|---|
| 52-week range | $3.10 - $5.08 |
| 50-day moving average | $3.76 |
| 200-day moving average | $4.13 |
| Wall St. target price | $4.00 |
| PE ratio | 19.5 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.16 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.12 from 2022-07-01
| 1 week (2022-06-24) | -9.83% |
|---|---|
| 1 month (2022-06-02) | -18.96% |
| 3 months (2022-03-29) | N/A |
| 6 months (2021-12-29) | -32.90% |
| 1 year (2021-07-02) | -27.61% |
|---|---|
| 2 years (2020-07-02) | -29.25% |
| 3 years (2019-07-02) | 9.51 |
| 5 years (2017-06-30) | 29.77 |
Valuing La Jolla Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of La Jolla Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
La Jolla Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, La Jolla Pharmaceutical shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
La Jolla Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.1 million.
The EBITDA is a measure of a La Jolla Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $52 million |
|---|---|
| Operating margin TTM | 4.68% |
| Gross profit TTM | $63.1 million |
| Return on assets TTM | 1.64% |
| Return on equity TTM | 0% |
| Profit margin | 10.08% |
| Book value | $-0.61 |
| Market capitalisation | $79.7 million |
TTM: trailing 12 months
We're not expecting La Jolla Pharmaceutical to pay a dividend over the next 12 months.
La Jolla Pharmaceutical's shares were split on a 1:50 basis on 13 January 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your La Jolla Pharmaceutical shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for La Jolla Pharmaceutical shares which in turn could have impacted La Jolla Pharmaceutical's share price.
Over the last 12 months, La Jolla Pharmaceutical's shares have ranged in value from as little as $3.1 up to $5.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while La Jolla Pharmaceutical's is 1.9578. This would suggest that La Jolla Pharmaceutical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.